Results 31 to 40 of about 1,185,249 (285)

G82S RAGE polymorphism is associated with Alzheimer’s disease

Frontiers in Bioscience-Elite, 2020
Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimer’s disease (AD) due to its ability to interact with amyloid beta and to elicit an inflammatory response. sRAGE, one of the splice variants of RAGE,
Rani Cathrine Chellappa, Palaniswamy Rani   +1 more
doaj   +1 more source

Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. [PDF]

, 2002
BACKGROUND: One of the signatures of Alzheimer's disease is the accumulation of aggregated amyloid protein, Abeta, in the brain. Abeta arises from cleavage of the Amyloid Precursor protein by beta and gamma secretases, which present attractive candidates
Brian Austen, Liu, C, Austen, B, Chibuu Liu, Sidera, C, Christina Sidera   +5 more
core   +1 more source

Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis

Translational Neurodegeneration, 2012
Alzheimer’s disease (AD) is a common neurodegenerative disease characterized clinically by progressive deterioration of memory, and pathologically by histopathological changes including extracellular deposits of amyloid-beta (A-beta) peptides forming ...
Dong Suzhen, Duan Yale, Hu Yinghe, Zhao Zheng   +3 more
doaj   +1 more source

Curcumin Inhibits the Primary Nucleation of Amyloid-Beta Peptide: A Molecular Dynamics Study

Biomolecules, 2020
The amyloid plaques are a key hallmark of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Amyloidogenesis is a complex long-lasting multiphase process starting with the formation of nuclei of amyloid peptides: a process ...
Irini Doytchinova, Mariyana Atanasova, Evdokiya Salamanova, Stefan Ivanov, Ivan Dimitrov   +4 more
doaj   +1 more source

Autoxidation Enhances Anti-Amyloid Potential of Flavone Derivatives

Antioxidants, 2021
The increasing prevalence of amyloid-related disorders, such as Alzheimer’s or Parkinson’s disease, raises the need for effective anti-amyloid drugs. It has been shown on numerous occasions that flavones, a group of naturally occurring anti-oxidants, can
Andrius Sakalauskas, Mantas Ziaunys, Ruta Snieckute, Vytautas Smirnovas   +3 more
doaj   +1 more source

Biomolecular studies in Alzheimer’s Disease models: investigations in vitro and in vivo [PDF]

, 2013
The Alzheimer’s disease (AD), the most prevalent form of age-related dementia, is a multifactorial and heterogeneous neurodegenerative disease. The molecular mechanisms underlying the pathogenesis of AD are yet largely unknown.
Lattanzio, Francesca <1982>
core   +1 more source

Intracellular accumulation of amyloid-beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease

Frontiers in Aging Neuroscience, 2010
Despite of long-standing evidence that beta-amyloid (Aβ) peptides have detrimental effects on synaptic function, the relationship between Aβ, synaptic and neuron loss is largely unclear.
Thomas A Bayer
doaj   +1 more source

Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-beta(38/40/42) in Frontotemporal Dementias and Primary Progressive Aphasias [PDF]

, 2010
Background/Aims: We determined cerebrospinal fluid (CSF) concentrations of amyloid-beta(A beta)(1-38), A beta(1-40), A beta(1-42), total tau and phospho-tau (p-tau) in order to study their differential expression in frontotemporal dementia (FTD, n = 25 ...
Hermann Esselmann, Mirko Bibl, Johannes Kornhuber, Markus Otto, Esselmann, Hermann, Rüther, Eckart, Otto, Markus, Lewczuk, Piotr, Kornhuber, Johannes, Eckart Rüther, Piotr Lewczuk, Brit Mollenhauer, Bibl, Mirko, Wolf, Stefanie, Jens Wiltfang, Mollenhauer, Brit, Wiltfang, Jens, Stefanie Wolf, Esselmann, Hermann; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Wiltfang, Jens; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Mollenhauer, Brit; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Bibl, Mirko; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Rüther, Eckart; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Rüther, Echart, Wolf, Stefanie; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Lewczuk, Piotr; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Otto, Markus; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany, Kornhuber, Johannes; aDepartment of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, and bKlinik für Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universität Duisburg-Essen, Essen, cUniversity of Göttingen and Paracelsus-Elena Klinik, Kassel, dDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, eDepartment of Psychiatry, University of Göttingen, Göttingen, fInstitute for Neurology, University of Ulm, Ulm, and gDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany   +27 more
core   +1 more source

Potential neuroprotective of trans-resveratrol a promising agent tempeh and soybean seed coats-derived against beta-amyloid neurotoxicity on primary culture of nerve cells induced by 2-methoxyethanol

Brazilian Journal of Biology, 2021
Resveratrol, a natural polyphenol found in tempeh, has not been investigated especially in vitro as a neuroprotective agent against 2-methoxyethanol (2-ME)-induced beta-amyloid cytotoxicity. Beta amyloid peptides (Aβ) could initiate neurotoxic events and
Y. Irnidayanti, D. R. Sutiono, N. Ibrahim, P. H. Wisnuwardhani, A. Santoso   +4 more
doaj   +1 more source

Amyloid-.BETA. peptide metabolism and Alzheimer's disease

Folia Pharmacologica Japonica, 2003
The deposition of amyloid-beta peptide (Abeta) causes the long-term pathological cascade of Alzheimer's disease (AD). Neprilysin is a rate-limiting peptidase, which participates in Abeta degradation in brain. As demonstrated by reverse genetics, the disruption of neprilysin gene causes an elevation in endogenous Abeta levels in the mouse brain in a ...
IWATA, Nobuhisa, SAIDO, Takaomi C.
openaire   +3 more sources